ダナパロイド (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ダナパロイド" in Japanese language version.

refsWebsite

Global rank Japanese rank

14doi.org

2^nd place

6^th place

13nih.gov

4^th place

24^th place

8worldcat.org

5^th place

19^th place

3karger.com

4,489^th place

low place

3elsevier.com

610^th place

915^th place

2schattauer.de

low place

1pmda.go.jp

6,690^th place

394^th place

1thieme-connect.de

low place

1omicsonline.org

low place

1biomedcentral.com

2,747^th place

2,369^th place

1wiley.com

222^nd place

498^th place

1nature.com

234^th place

363^rd place

1haematologica.org

low place

biomedcentral.com

bmcgastroenterol.biomedcentral.com

Fujiyama, Shunichiro; Saitoh, Satoshi; Kawamura, Yusuke; Sezaki, Hitomi; Hosaka, Tetsuya; Akuta, Norio; Kobayashi, Masahiro; Suzuki, Yoshiyuki et al. (2017-12). “Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome” (英語). BMC Gastroenterology 17 (1): 112. doi:10.1186/s12876-017-0668-8. ISSN 1471-230X. PMC 5657117. PMID 29070023.

doi.org

“Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats”. Crit Care 12 (2): R43. (2008). doi:10.1186/cc6851. PMC 2447588. PMID 18380908.
Meuleman, D.G. (1992). “Orgaran (Org 10172): Its Pharmacological Profile in Experimental Models” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2): 58–65. doi:10.1159/000216296. ISSN 1424-8840.
Ofosu, F.A. (1992). “Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849)” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2): 66–72. doi:10.1159/000216297. ISSN 1424-8840.
“Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study”. Crit Care 11 (5): R102. (2007). doi:10.1186/cc6119. PMC 2556745. PMID 17854496.
“Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004”. Thromb. Haemost. 95 (6): 967–81. (June 2006). doi:10.1160/TH05-07-0489. PMID 16732376.
Magnani, Harry; Gallus, Alex (2006). “Heparin-induced thrombocytopenia (HIT): A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004” (英語). Thrombosis and Haemostasis 95 (06): 967–981. doi:10.1160/TH05-07-0489. ISSN 0340-6245.
Bidlingmaier, Christoph; Magnani, Harry N.; Girisch, Monika; Kurnik, Karin (2006). “Safety and Efficacy of Danaparoid (Orgaran®) Use in Children” (英語). Acta Haematologica 115 (3-4): 237–247. doi:10.1159/000090941. ISSN 0001-5792.
Magnani, H.N. (2010-04). “An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran®)” (英語). Thrombosis Research 125 (4): 297–302. doi:10.1016/j.thromres.2009.06.006.
Magnani, H.N. (2010-04). “A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis” (英語). Thrombosis Research 125 (4): e171–e176. doi:10.1016/j.thromres.2009.10.008.
Jpj, Wester (2012). “Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? An Analysis of Case Reports”. Journal of Biometrics & Biostatistics 01 (09). doi:10.4172/scientificreports.423.
Fujiyama, Shunichiro; Saitoh, Satoshi; Kawamura, Yusuke; Sezaki, Hitomi; Hosaka, Tetsuya; Akuta, Norio; Kobayashi, Masahiro; Suzuki, Yoshiyuki et al. (2017-12). “Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome” (英語). BMC Gastroenterology 17 (1): 112. doi:10.1186/s12876-017-0668-8. ISSN 1471-230X. PMC 5657117. PMID 29070023.
Kato, Koji; Sakaguchi, Hirotoshi; Muramatsu, Hideki; Sekiya, Yuko; Kawashima, Nozomu; Narita, Atsushi; Doisaki, Sayoko; Watanabe, Nobuhiro et al. (2018-03). “Danaparoid reduces transplant-related mortality in stem cell transplantation for children” (英語). Pediatric Transplantation 22 (2): e13099. doi:10.1111/petr.13099.
Machida, S; Onizuka, M; Toyosaki, M; Aoyama, Y; Kawai, H; Amaki, J; Hara, R; Ichiki, A et al. (2017-02). “Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy” (英語). Bone Marrow Transplantation 52 (2): 307–309. doi:10.1038/bmt.2016.270. ISSN 0268-3369.
Lubenow, Norbert; Warkentin, Theodore E.; Greinacher, Andreas; Wessel, Antje; Sloane, Debi-Ann; Krahn, Erica L.; Magnani, Harry N. (2006-01). “Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s” (英語). Thrombosis Research 117 (5): 507–515. doi:10.1016/j.thromres.2005.04.011.

elsevier.com

linkinghub.elsevier.com

Magnani, H.N. (2010-04). “An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran®)” (英語). Thrombosis Research 125 (4): 297–302. doi:10.1016/j.thromres.2009.06.006.
Magnani, H.N. (2010-04). “A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis” (英語). Thrombosis Research 125 (4): e171–e176. doi:10.1016/j.thromres.2009.10.008.
Lubenow, Norbert; Warkentin, Theodore E.; Greinacher, Andreas; Wessel, Antje; Sloane, Debi-Ann; Krahn, Erica L.; Magnani, Harry N. (2006-01). “Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s” (英語). Thrombosis Research 117 (5): 507–515. doi:10.1016/j.thromres.2005.04.011.

haematologica.org

“Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid”. Haematologica 90 Suppl: ECR29. (November 2005). PMID 16266920.

karger.com

Meuleman, D.G. (1992). “Orgaran (Org 10172): Its Pharmacological Profile in Experimental Models” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2): 58–65. doi:10.1159/000216296. ISSN 1424-8840.
Ofosu, F.A. (1992). “Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849)” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2): 66–72. doi:10.1159/000216297. ISSN 1424-8840.
Bidlingmaier, Christoph; Magnani, Harry N.; Girisch, Monika; Kurnik, Karin (2006). “Safety and Efficacy of Danaparoid (Orgaran®) Use in Children” (英語). Acta Haematologica 115 (3-4): 237–247. doi:10.1159/000090941. ISSN 0001-5792.

nature.com

Machida, S; Onizuka, M; Toyosaki, M; Aoyama, Y; Kawai, H; Amaki, J; Hara, R; Ichiki, A et al. (2017-02). “Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy” (英語). Bone Marrow Transplantation 52 (2): 307–309. doi:10.1038/bmt.2016.270. ISSN 0268-3369.

nih.gov

pubmed.ncbi.nlm.nih.gov

“Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats”. Crit Care 12 (2): R43. (2008). doi:10.1186/cc6851. PMC 2447588. PMID 18380908.
“Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study”. Crit Care 11 (5): R102. (2007). doi:10.1186/cc6119. PMC 2556745. PMID 17854496.
Fernandez, F. A.; Buchanan, M. R.; Hirsh, J.; Fenton, J. W.; Ofosu, F. A. (1987-06-03). “Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits”. Thrombosis and Haemostasis 57 (3): 286–293. ISSN 0340-6245. PMID 3116701.
“[Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases”] (ドイツ語). Hamostaseologie 27 (2): 89–97. (May 2007). PMID 17479171.
“Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004”. Thromb. Haemost. 95 (6): 967–81. (June 2006). doi:10.1160/TH05-07-0489. PMID 16732376.
Fujiyama, Shunichiro; Saitoh, Satoshi; Kawamura, Yusuke; Sezaki, Hitomi; Hosaka, Tetsuya; Akuta, Norio; Kobayashi, Masahiro; Suzuki, Yoshiyuki et al. (2017-12). “Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome” (英語). BMC Gastroenterology 17 (1): 112. doi:10.1186/s12876-017-0668-8. ISSN 1471-230X. PMC 5657117. PMID 29070023.
“Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid”. Haematologica 90 Suppl: ECR29. (November 2005). PMID 16266920.
Chong, B. H.; Gallus, A. S.; Cade, J. F.; Magnani, H.; Manoharan, A.; Oldmeadow, M.; Arthur, C.; Rickard, K. et al. (2001-11). “Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study”. Thrombosis and Haemostasis 86 (5): 1170–1175. ISSN 0340-6245. PMID 11816702.

pmc.ncbi.nlm.nih.gov

“Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats”. Crit Care 12 (2): R43. (2008). doi:10.1186/cc6851. PMC 2447588. PMID 18380908.
“Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study”. Crit Care 11 (5): R102. (2007). doi:10.1186/cc6119. PMC 2556745. PMID 17854496.
Fujiyama, Shunichiro; Saitoh, Satoshi; Kawamura, Yusuke; Sezaki, Hitomi; Hosaka, Tetsuya; Akuta, Norio; Kobayashi, Masahiro; Suzuki, Yoshiyuki et al. (2017-12). “Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome” (英語). BMC Gastroenterology 17 (1): 112. doi:10.1186/s12876-017-0668-8. ISSN 1471-230X. PMC 5657117. PMID 29070023.

ncbi.nlm.nih.gov

omicsonline.org

Jpj, Wester (2012). “Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? An Analysis of Case Reports”. Journal of Biometrics & Biostatistics 01 (09). doi:10.4172/scientificreports.423.

pmda.go.jp

info.pmda.go.jp

“オルガラン静注1250単位添付文書”. www.info.pmda.go.jp. 2021年12月22日閲覧。

schattauer.de

thieme-connect.de

Magnani, Harry; Gallus, Alex (2006). “Heparin-induced thrombocytopenia (HIT): A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004” (英語). Thrombosis and Haemostasis 95 (06): 967–981. doi:10.1160/TH05-07-0489. ISSN 0340-6245.

wiley.com

onlinelibrary.wiley.com

Kato, Koji; Sakaguchi, Hirotoshi; Muramatsu, Hideki; Sekiya, Yuko; Kawashima, Nozomu; Narita, Atsushi; Doisaki, Sayoko; Watanabe, Nobuhiro et al. (2018-03). “Danaparoid reduces transplant-related mortality in stem cell transplantation for children” (英語). Pediatric Transplantation 22 (2): e13099. doi:10.1111/petr.13099.

worldcat.org

search.worldcat.org

Meuleman, D.G. (1992). “Orgaran (Org 10172): Its Pharmacological Profile in Experimental Models” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2): 58–65. doi:10.1159/000216296. ISSN 1424-8840.
Ofosu, F.A. (1992). “Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849)” (英語). Pathophysiology of Haemostasis and Thrombosis 22 (2): 66–72. doi:10.1159/000216297. ISSN 1424-8840.
Fernandez, F. A.; Buchanan, M. R.; Hirsh, J.; Fenton, J. W.; Ofosu, F. A. (1987-06-03). “Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits”. Thrombosis and Haemostasis 57 (3): 286–293. ISSN 0340-6245. PMID 3116701.
Magnani, Harry; Gallus, Alex (2006). “Heparin-induced thrombocytopenia (HIT): A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004” (英語). Thrombosis and Haemostasis 95 (06): 967–981. doi:10.1160/TH05-07-0489. ISSN 0340-6245.
Bidlingmaier, Christoph; Magnani, Harry N.; Girisch, Monika; Kurnik, Karin (2006). “Safety and Efficacy of Danaparoid (Orgaran®) Use in Children” (英語). Acta Haematologica 115 (3-4): 237–247. doi:10.1159/000090941. ISSN 0001-5792.
Fujiyama, Shunichiro; Saitoh, Satoshi; Kawamura, Yusuke; Sezaki, Hitomi; Hosaka, Tetsuya; Akuta, Norio; Kobayashi, Masahiro; Suzuki, Yoshiyuki et al. (2017-12). “Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome” (英語). BMC Gastroenterology 17 (1): 112. doi:10.1186/s12876-017-0668-8. ISSN 1471-230X. PMC 5657117. PMID 29070023.
Machida, S; Onizuka, M; Toyosaki, M; Aoyama, Y; Kawai, H; Amaki, J; Hara, R; Ichiki, A et al. (2017-02). “Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy” (英語). Bone Marrow Transplantation 52 (2): 307–309. doi:10.1038/bmt.2016.270. ISSN 0268-3369.
Chong, B. H.; Gallus, A. S.; Cade, J. F.; Magnani, H.; Manoharan, A.; Oldmeadow, M.; Arthur, C.; Rickard, K. et al. (2001-11). “Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study”. Thrombosis and Haemostasis 86 (5): 1170–1175. ISSN 0340-6245. PMID 11816702.